{"id":"W3005887319","doi":"10.1097/01.hs9.0000560956.60646.c2","title":"PF668 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Monocytosis; Refractory (planetary science); Internal medicine; Interleukin-3 receptor; Oncology; Phases of clinical research; Ruxolitinib; Myeloid; Clinical trial; Gastroenterology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00321744,0.001197573,0.001302849,0.0003237095,0.0003774155,0.0008839252,0.0006403563,0.001232948,0.003797557],"category_scores_gemma":[0.001635451,0.0003714196,0.001169402,0.0003285573,0.0007534853,0.0009621556,0.0002971704,0.002459502,0.0007983829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007743259,"about_ca_system_score_gemma":0.00112129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005085894,"about_ca_topic_score_gemma":0.001134407,"domain_scores_codex":[0.9992163,0.0004308049,0.00005894453,0.00009315379,0.00008180665,0.0001189606],"domain_scores_gemma":[0.9989223,0.0002422244,0.000235618,0.00008231419,0.00007473701,0.0004426674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7451349,0.03824563,0.01530427,0.0008095774,0.001688772,0.0006382749,0.0003712225,0.003585073,0.04141977,0.0003385946,0.008591094,0.1438728],"study_design_scores_gemma":[0.4838237,0.4682814,0.03170497,0.00008967765,0.0009995219,0.0009415218,0.0000808445,0.001614888,0.006492889,0.0003392154,0.005585362,0.00004596565],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989035,0.00310949,0.0008192239,0.001093257,0.0001336562,0.001660308,0.002061506,0.0001101767,0.001977307],"genre_scores_gemma":[0.9862911,0.001868595,0.001861862,0.001253877,0.0003087739,0.001492487,0.005088093,0.00003229126,0.00180286],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003797557,"threshold_uncertainty_score":0.0170157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02421052598918092,"score_gpt":0.3103908181273837,"score_spread":0.2861802921382028,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}